Open AccessTune the channel: TRPM8 targeting in prostate cancer
Author(s) -
Alessandro Alaimo,
Dario De Felice,
Sacha Genovesi,
Marco Lorenzoni,
Andrea Lunardi
Publication year - 2021
Publication title -
oncoscience
Language(s) - English
Resource type - Journals
ISSN - 2331-4737
DOI - 10.18632/oncoscience.543
Subject(s) - prostate cancer , trpm8 , prostate , channel (broadcasting) , medicine , cancer , oncology , computer science , transient receptor potential channel , telecommunications , receptor , trpv1
The therapeutic landscape of cancer treatments is quickly evolving thanks to the advent of precision oncology. Discovery of novel druggable targets and more reliable biomarkers is a primary objective towards personalized strategies of cancer treatment. Highly expressed in the prostate epithelium within the human body, Transient Receptor Potential subfamily M member 8 (TRPM8) levels rise in primary and hormone naïve metastatic prostate cancer (PCa) lesions, which makes this channel an interesting prototype of molecular target. Recently, by combining a multidisciplinary approach to an in vitro genetic platform, we demonstrated that the combination of potent TRPM8 agonists with X-rays induces a massive apoptotic response in radioresistant pre-malignant and malignant models of primary prostate lesions. As well, TRPM8 activation enhances the efficacy of docetaxel or enzalutamide in eradicating hormone naïve metastatic PCa cells. Overall, our findings provide a solid rationale for pursuing the pre-clinical and clinical study of TRPM8 as a valuable target for future approaches of precise oncology in PCa.